In a few reports, drug inhibition of GSK3β has been shown to improve maturation and antitumor activity of NK cells with elevated GSK3β, such as IL-15 expanded NK cells or NK cells isolated from AML patients [5,6,7]. This evidence concerns the gene IL15 and acute myeloid leukemia.